A Study of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage

Johnson & Johnson Consumer Inc. (J&JCI)87 enrolled

Overview

The purpose of this study is to proactively collect customer feedback on the performance aspects and risk factors of Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Common Cold Sinusitis Hypersensitivity

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 18 years or older who has personally used or administered the nasal drops/spray to a child * Has personally used or administered to a child, the Nasal Drops/Spray at least once within the past 6 months * Able to read, write, speak, and understand German * Has internet access to complete an on-line survey * Intends to complete the survey * Individual has signed the informed consent document (ICD) Exclusion Criteria: \- Is an employee/contractor or immediate family member of the principal investigator (PI), Schlesinger group, product perceptions limited (PPL) Insights or sponsor of this study

Locations (1)

Schlesinger Group

Berlin, Germany

Outcomes

Primary Outcomes

Participant Feedback on the Performance Aspects of Olynth Nasal Saline Drops

Participant feedback on the performance aspects of Olynth Nasal Saline Drops will be assessed via electronic survey.

Time frame: Up to 1 month and 14 days

Participant Feedback on the Performance Aspects of Olynth Nasal Saline Spray

Participant feedback on the performance aspects of Olynth Nasal Saline Spray will be assessed via electronic survey.

Time frame: Up to 1 month and 14 days

Participant Feedback on the Performance Aspects of Olynth Ectomed Nasal Spray

Participant feedback on the performance aspects of Olynth Ectomed Nasal Spray will be assessed via electronic survey.

Time frame: Up to 1 month and 14 days

Number of Participants with Adverse Events (AEs)

An AE is any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, whether or not related to the investigational device.

Time frame: Up to 1 month and 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.